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0.01). Immunoblot analyses confirmed a significant increase inBasic fibroblast growth factor expression is increased in human
FGF-2 protein expression in kidneys with interstitial scarring.renal fibrogenesis and may mediate autocrine fibroblast prolif-
In situ hybridization studies demonstrated low-level detectioneration.
of FGF-2 mRNA in normal kidneys. However, FGF-2 mRNABackground. Interstitial fibroblasts play a critical role in
expression was robustly up-regulated in interstitial and tubularrenal fibrogenesis, and autocrine proliferation of these cells
cells in end-stage kidneys, indicating that these cells are themay account for continuous matrix synthesis. Basic fibroblast
source of excess FGF-2 protein. Primary cortical fibroblastsgrowth factor (FGF-2) is mitogenic for most cells and exerts
express FGF-2 and FGFR-1 in vitro. FGF-2 induced a robustintracrine, autocrine, and paracrine effects on epithelial and
growth response in these cells that could be blocked specificallymesenchymal cells. The aims of the present studies were to
by a neutralizing FGF-2 antibody. Interestingly, the additionlocalize and quantitate the expression of FGF-2 in normal and
of the neutralizing antibody alone did reduce basal proliferationpathologic human kidneys and to study the in vitro effects of
up to 31.5%. In addition, FGF-2 induced expression of a-smoothFGF-2 on proliferation, differentiation, and matrix production
muscle actin up to 1.6-fold, but no significant effect was observedof isolated cortical kidney fibroblasts.
on the synthesis of collagen type I and fibronectin. Finally,Methods. FGF-2 protein expression was localized by immu-
staining for MIB-1 revealed a good correlation of interstitialnofluoresence double labelings in normal and fibrotic human
FGF-2 positivity with interstitial and tubular proliferative activ-kidneys. Subsequently, interstitial FGF-2 labeling was deter-
ity (r 5 0.71, P , 0.01 for interstitial proliferation, N 5 30).mined semiquantitatively in 8 normal kidneys and 39 kidneys
Conclusions. Interstitial FGF-2 protein and mRNA expres-with variable degrees of interstitial fibrosis and was correlated
sion correlate with interstitial scarring. FGF-2 is a strong mito-with the morphometrically determined interstitial cortical vol-
gen for cortical kidney fibroblasts and may promote autocrineume. In addition, FGF-2 expression was quantitated by immu-
fibroblast growth. Expression of FGF-2 correlates with intersti-noblot analysis in three normal and six fibrotic kidneys. FGF-2
tial and tubular proliferation in vivo.mRNA was localized by in situ hybridizations. Seven primary
cortical fibroblast lines were established, and expression of
FGF-2 and FGF receptor-1 (FGFR-1) were examined. The ef-
fects of FGF-2 on cell proliferation were determined by bromo- Fibrosis is a process that is characterized by excessivedeoxyuridine incorporation and cell counts, those on differenti-
deposition of matrix components compromising organation into myofibroblasts by staining for a-smooth muscle actin,
function because of replacement of normal organ tissue.and those on matrix synthesis by enzyme-linked immunosor-
bent assay for collagen type I and fibronectin. Finally, prolifera- Tissue fibrosis can affect almost any organ but prefers
tive activity in vivo was evaluated by expression of MIB-1 (Ki-67 tissues with common inflammations, such as the skin,
antigen). the lung, the liver, and the kidney [1]. Inflammation isResults. In normal kidneys, FGF-2 expression was confined
caused by the recruitment of infiltrating inflammatoryto glomerular, vascular, and a few tubular as well as interstitial
cells such as lymphocytes and monocytes/macrophages.fibroblast-like cells. The expression of FGF-2 protein was in-
creased in human kidneys, with tubulointerstitial scarring cor- Inflammatory infiltration is followed by activation and
relating with the degree of interstitial fibrosis (r 5 0.84, P , proliferation of matrix-producing cells, mainly fibro-
blasts, which synthesize excessive amounts of extracellu-
lar matrix. Cytokines seem to play a decisive role inKey words: FGF-2, fibrosis, kidney, interstitial fibroblast, cell prolifera-
tion. the pathogenesis of organ scarring. Human fetuses heal
without scar early in gestation and begin to show scarringReceived for publication July 27, 1999
late in development [2]. The anatomical difference be-and in revised form October 27, 1999
Accepted for publication November 1, 1999 tween the scarless fetal wound healing and the adult scar
formation lies in the organization of matrix. WhereasÓ 2000 by the International Society of Nephrology
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fibroblasts deposit matrix in an organized fashion, similar remains controversial. Recently, Floege et al analyzed
FGF-2 expression in normal human kidneys using fourto normal skin in fetal wounds, adult wounds are charac-
terized by the deposition of disorganized collagen fibers different antibodies, and localized it most consistently
to distal tubular epithelial and vascular smooth muscle[3]. Studies by Whitby and Ferguson have demonstrated
that the differential expression of certain cytokines is cells [18]. FGF-2 is mitogenic for mesangial [19], proxi-
mal-tubular epithelial [20], glomerular endothelial [21],one of the key reasons for scar formation. Transforming
growth factor-b (TGF-b) immunostaining, for example, and glomerular epithelial cells [15]. Floege et al demon-
strated that FGF-2 was synthesized by mesangial cellswas absent in fetal mouse wounds and was abundant in
neonatal and adult mouse wounds [4]. Another cytokine in vitro and in vivo [14]. Furthermore, FGF-2 infusions
into rats injected with an antimesangial cell antibodythat was markedly up-regulated in postnatal wounds with
fibrosis was basic fibroblast growth factor (FGF-2). Whitby (anti-Thy 1.1) resulted in a fourfold increase in glomeru-
lar cell proliferation [22] and led to increased podocyteand Ferguson demonstrated that, similar to TGF-b,
FGF-2 is present in neonatal and adult mouse lips but injury and glomerulosclerosis in rats with membranous
nephropathy [23]. Similarly, treatment of rats for 8 andcannot be detected in fetal mouse lip wounds [4]. Thus,
similar to TGF-b, FGF-2 may play an important role in 13 weeks with subcutaneous FGF-2 injections resulted
in focal segmental glomerulosclerosis, with an increasethe scarring process.
In the kidney, chronic tubulointerstitial fibrosis is the of the peritubular interstitium [24]. Finally, Ray et al
studied a transgenic mouse model of HIV-associatedfinal common pathway of glomerular, vascular, or inter-
stitial inflammations, often resulting in end-stage renal nephropathy and described increased interstitial staining
for FGF-2 colocalized with extracellular matrix [25].disease [5]. The severity of chronic tubulointerstitial dis-
ease is the single best histologic correlate of the decline The aims of the present study were the evaluation of
FGF-2 expression in normal and fibrotic human kidneysin renal function and prognosis for organ function [1, 6].
As in other scarring processes, a number of cytokines and its potential role in renal fibrogenesis.
have been implicated in renal fibrogenesis, including plate-
let-derived growth factor (PDGF) and TGF-b. PDGF is
METHODS
a strong mitogen for some but not all fibroblasts [7], and
MaterialsPDGF-BB has been shown to cause interstitial cell prolif-
eration, the appearance of myofibroblasts, and kidney Rabbit polyclonal antibody to FGF-2 (Ab-2) and mouse
monoclonal antibody to FGF receptor-1 (FGFR-1) werefibrosis in rats if given intravenously in high doses [8].
TGF-b affects all phases of wound healing, including the purchased from Calbiochem (La Jolla, CA, USA). Hu-
man recombinant FGF-1 and FGF-2 were from R&Dinflammatory response and matrix accumulation [9, 10].
Increased expression of TGF-b1 has been described in a Systems (Minneapolis, MN, USA), as was the neutraliz-
ing goat polyclonal antibody to FGF-2. Mouse mono-variety of animal models and human diseases associated
with renal fibrosis [reviewed in 1]. However, the role of clonal antibody to collagen type I was obtained from
Southern Biotechnology (Birmingham, AL, USA). Poly-other cytokines, such as FGF-2, is less well defined.
FGF-2 belongs to the family of fibroblast growth and clonal rabbit antibody to fibronectin antibody was pur-
chased from Sigma (St. Louis, MO, USA), and mousedifferentiation factors that currently contains nine mem-
bers [11]. Up-regulated expression of FGF-2 has been monoclonal antibody to heparan sulfate was from Boeh-
ringer Mannheim (Mannheim, Germany). For cell char-linked to fibrogenesis in a number of animal models.
Injection of FGF-2 into subcutaneous tissue of newborn acterization, the following additional mouse monoclonal
antibodies were used: anticytokeratin (Dako, Carpin-mice caused slight fibrotic changes after seven days of
injection, whereas simultaneous application with TGF-b teria, CA, USA), antivimentin (Boehringer Mannheim),
anti-factor VIII (Dako), anti-human lymphocyte anti-resulted in persistent skin fibrosis [12]. Moreover, FGF-2
is a strong mitogen for pulmonary fibroblasts and hepatic gen-DR (HLA-DR) (Dako), anti–a-smooth muscle ac-
tin (Paesel1Lorei, Wiesbaden, Germany), anticollagenstellate cells, and has thus been implicated in the patho-
genesis of lung and liver fibrosis, although the exact role type III (Southern Biotechnology), anti-CD 44 (Phar-
mingen, San Diego, CA, USA), anti-CD 54, and anti-CDremains to be elucidated.
Regarding the kidney, FGF-2 protein was isolated 68 (Dako). The mouse monoclonal antibody to collagen
type IV was a generous gift from Steven Gay (Universityfrom whole kidney homogenates as early as 1985 [13].
Floege et al, as well as Takeuchi et al, reported strong of Zu¨rich, Zu¨rich, Switzerland). Trypsin-ethylenediamine-
tetraacetic acid (EDTA), Dulbecco’s modified Eagle’simmunostaining in Bowman’s capsule, the glomerular
mesangium, blood vessels, and the interstitium, as well as medium (DMEM), Iscove’s modified Dulbecco’s me-
dium, and fetal calf serum (FCS) were obtained fromwithin some tubules in rats [14, 15], although their results
could not be confirmed by all investigators [16, 17] and GIBCO BRL Ltd. (Paisley, Scotland). Cell culture dishes
were from Becton Dickinson (Franklin Lakes, NJ, USA).the exact localization of FGF-2 protein in the kidney
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Patient material formaldehyde using 1 3 MOPS, pH 7.0, as the running
buffer. Photographs of ethidium-bromide–stained gelsKidney tissues from 39 patients with primary and sec-
were taken under ultraviolet illumination. RNA was sub-ondary renal diseases and a variable degree of tubuloin-
sequently transferred to a nylon membrane (Hybond N;terstitial fibrosis were used in this study. Tissues included
Amersham, Arlington Heights, IL, USA) by capillary32 biopsies and 7 nephrectomy specimens. The nephrec-
transfer for 12 hours with 20 3 standard saline citratetomies were performed in patients with end-stage renal
(SSC) as the transfer buffer. Blots were baked at 808Cdisease caused by intractable hypertension or recurrent
and prehybridized for one hour at 688C in prehybridiza-urinary tract infections. The use of parts of nephrectomy
tion solution containing 0.5 mol/L Na2HPO4 buffer (pHspecimens or kidney biopsies for research purposes was
7.2), 0.5 mol/L EDTA (pH 8.0), 25% sodium dodecylapproved by the ethics committee of the Georg-August-
sulfate (SDS), and 1.5% blocking reagent. FGF-2 specificUniversity, and written consent was obtained from all
oligonucleotides (R&D Systems) were labeled with di-patients prior to nephrectomy or kidney biopsy. Normal-
goxigenin using a kit (Boehringer Mannheim) accordingappearing kidney tissue from kidneys that proved either
to the manufacturer’s instructions. Hybridizations wereunsuitable for transplantation or were explanted because
performed overnight at 588C using the prehybridizationof tumor nephrectomies were used as controls (N 5 8).
solution. After washing, anti-DIG alkaline phosphate and
disodium 3-(4-methoxyspiro{1,2-dioxetane-3,29-(59-chloro)Cell culture
tricyclo[3.3.1.13,7]decan}-4-yl)phenyl phosphate (CSPD)Human medullary fibroblast cell lines Tk 173 (obtained
substrate (both Boehringer Mannheim) were added, andfrom a normal kidney) and Tk 188 (from a kidney with
autoradiograms were obtained.tubulointerstitial fibrosis) have been characterized pre-
Subsequently, immunoblots were performed as de-viously [26] and were cultured in DMEM supplemented
scribed previously [27]. Briefly, lysates from Tk 173 andwith 10% FCS, penicillin (100 U/mL), and streptomycin
Tk 188 fibroblasts were obtained by lysis with a deter-(100 U/mL). For the isolation of primary human renal
gent-based buffer containing 0.4% sodium deoxycholate,fibroblasts, cortical parts of renal biopsy cylinders or ne-
1% NP-40, 1.9% EGTA, and 10 mmol/L Tris (pH 7.4).
phrectomy specimens were cut and emerged in DMEM
One hundred micrograms of total cellular protein and
medium with 20% FCS and penicillin/streptomycin in
50 ng FGF-2 control protein were run on an 18% SDS-
the previously mentioned concentrations. When cells had polyacrylamide electrophoresis gel and transferred to a
grown to confluence, they were characterized by immuno- nitrocellulose membran (Hybonde ECLe; Amersham)
fluorescence for cytokeratin, vimentin, a-smooth muscle by electroblotting. Membranes were stained with Pon-
actin, collagen types I, III, IV, factor VIII, CD 68, and ceau red to control for adequate transfer and equally
HLA-DR. Cells that were positive for vimentin and at loaded amounts. After blocking, the membrane was in-
least collagen types I and III, and negative for cytokera- cubated with the respective antibody (anti–FGF-2 in a
tin, factor VIII and HLA class II were considered to be concentration of 1:40) followed by the secondary anti-
fibroblasts and were used for induction assays in passages 2 body (donkey-antirabbit, horseradish peroxidase-linked,
through 8. For detection of heparan sulfate proteoglycane concentration 1:3000; Amersham). Positive reaction pro-
expression, fluorescence activated cell sorting (FACS) ducts were identified by enhanced chemiluminescence
analysis was performed as described previously [26]. (ECL; Amersham) according to the manufacturer’s pro-
tocol.
Specificity of the basic fibroblast growth
factor antibody Immunhistochemical staining for basic fibroblast
growth factor and morphometric evaluation ofTo determine the specificity of the applied antibody,
interstitial volumeFGF-2 expression in Tk 173 and Tk 188 fibroblasts (which
are easier to culture than primary fibroblasts) was first Tissue from normal human kidneys, renal biopsies,
analyzed by immunocytochemistry as described pre- and end-stage kidneys were snap frozen in liquid nitro-
viously, using the anti–FGF-2 and the secondary FITC- gen. Sections of 4 to 6 mm were cut, mounted on micro-
antirabbit antibodies at concentrations of 1:20 [27]. For scope slides, and fixed in ice-cold acetone for 10 minutes.
Northern blot analyses, total cellular RNA was extracted Sections were then allowed to dry, and unspecific binding
from cultured cells using RNA-cleane (AGS, Heidel- was blocked by incubation with goat serum. Anti–FGF-2
berg, Germany) according to the manufacturer’s instruc- antibody was added in a concentration of 1:20. After
tions. Concentration of RNA was determined by ab- incubation for 60 minutes and several washes in phos-
sorbance at 260 nm, and samples were stored at 2808C phate-buffered saline (PBS), FITC-antirabbit was added
prior to use. Northern blot analysis was performed as in a concentration of 1:20. Positivity was evaluated with
described [28]. Briefly, 40 mg of total RNA were electro- an Axiophot S100 microscope (Zeiss, Jena, Germany).
Interstitial cortical staining for FGF-2 was rated by twophoresed on a 1.0% agarose gel containing 2.2 mol/L
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blinded investigators as in normal kidneys (1), increased Piscataway, NJ, USA). The vector was linearized with
the appropriate enzyme, and FGF-2 sense/antisense ri-(11), robustly increased (111), or absent (2). Nega-
tive controls consisted in substitution of the primary anti- boprobes were synthesized and labeled with digoxigenin
by in vitro transcription with the DIG RNA labelingbody with an irrelevant rabbit polyclonal antibody or PBS.
In selected sections, double labelings were performed kit (Boehringer Mannheim) as described [31]. Tissue
sections were mounted on Sectionlocke slides (Poly-to characterize FGF-2–positive interstitial cells. In that
case, an addition of the anti–FGF-2 antibody was followed sciences, Eppelheim, Germany), briefly heated to 508C
to ensure fixation, dried for 30 minutes, and fixed in 3%by staining for a-smooth muscle actin, vimentin, cytoker-
atin, HLA-DR, CD 44, CD 54, and CD 68. FITC-anti- paraformaldehyde for 7 minutes. Washing in PBS and
2 3 SSC was followed by prehybridization for 60 minutesrabbit and the appropriate rhodamin-labeled antibody
were added sequentially at a concentration of 1:20. Pho- at 438C in hybridization buffer (Amersham) containing
50% formamide (Sigma). Hybridization was then per-tographs were taken either by double or by sequential
exposure using Zeiss camera and software (MC 200 Chip). formed in 40 to 60 mL hybridization buffer per section
containing the cRNA probe at a concentration of 200Selected sections from normal and fibrotic kidneys
were also paraffin embedded after fixation in formalde- ng/mL, followed by washing in 2 3 SSC for 5 minutes
at 378C and twice for 15 minutes in 0.1 3 SSC, SDS athyde using a standard avidin-biotin complex (ABC)
method, as described previously [27]. 688C. After a final wash in 100 mmol/L Tris-HCl and
150 mmol/L NaCl for five minutes at room temperature,For morphometric evaluation, all tissue specimens
were fixed in 4% buffered formalin solution (pH 7.4) 1% blocking buffer and 10% goat serum (Dako) were
added, and the sections were incubated with a 1:500and embedded in paraffin. Tissue sections were stained
for trichrome or PAS, and point counting was performed dilution of alkaline-phosphatase conjugated anti-DIG
antibody for two hours at room temperature. Detectionas described by Bohle et al [29]. Only those specimens
containing at least five glomeruli were evaluated. Five was performed after several washes in 100 mmol/L Tris-
HCl, 150 mmol/L NaCl with detection buffer contain-projection fields of the cortex were examined per kidney
using a lattice of 1 cm at a magnification of 3250, discrim- ing 0.18 mg/mL 5-bromo-4-chloro-3-indolyl-phosphate
(BCIP), 0.34 mg/mL nitro blue tetrazolium (NBT), andinating between interstitium, tubular epithelia, glomer-
uli, and vasculature. Big blood vessels were ignored. The 240 mg/mL levamisole. After 12 hours, color reaction
was stopped by washing in 10 mmol/L Tris (pH 8) andvalue for the interstitium was expressed as a percentage
of the analyzed cortex. 1 mmol/L EDTA for five minutes, and coverslips were
mounted. Sections from human synovia, which is known
Quantitation of basic fibroblast growth to express FGF-2 abundantly, served as positive control.
factor expression
Proliferation assayExpression of FGF-2 protein was quantitated by im-
munoblot analysis. Briefly, lysates were obtained from Proliferation studies in primary cortical fibroblasts
were performed using nonradioactive bromodeoxyuri-six kidneys with considerable interstitial scarring and
three control kidneys. Immunoblots were performed as dine incorporation assays (Amersham) based on the
method by Gratzner [32]. Four 3 103 cells were plateddescribed earlier in this article using 100 mg of protein
and 50 ng of FGF-2 recombinant protein as positive per well in 96-well microtiter plates containing DMEM
medium with the usual supplements and incubated over-control. After staining for Ponceau red, blots were ana-
lyzed densitometrically for later normalization. Positive night to allow cell attachment. Cells were then made
quiescent by replacement of DMEM medium with Is-reaction products were again identified by chemilumi-
nescence using a Fluor-Se Multiimager (Bio-Rad, Her- cove’s medium and subsequent incubation for 24 hours.
In preliminary experiments, cytokines were added, andcules, CA, USA), and densitometric analysis was per-
formed with Multi-Analyste software (Bio-Rad). proliferation was measured after 24, 48, 72, and 96
hours. FGF-2 was used in concentrations of 0.1, 1, 10,
Vector assembly and in situ hybridization for basic and 100 ng/mL (equivalent to 5.5 3 10212 mol/L, 5.5 3
fibroblast growth factor 10211 mol/L, 5.5 3 10210 mol/L, and 5.5 3 1029 mol/L,
respectively). In a second set of experiments, 1 ng/mLIn situ hybridizations were performed on 6 mm sec-
tions of snap-frozen tissue from freshly explanted kid- FGF-2 was added, and bromodeoxyuridine incorpora-
tion was measured after 72 hours. The specificity of theneys using a digoxigenin-labeled cRNA probe. FGF-2
cDNA was purchased from R&D Systems, digested with response to FGF-2 was determined by addition of a neu-
tralizing FGF-2 antibody in a concentration of 10 mg/mLHind III and BamHI, and cloned into pBS SK II (Stra-
tagene, La Jolla, CA, USA) as described [30]. The new (which had been determined in titration experiments
with Tk 173 fibroblasts) or a nonrelevant IgG. Bothvector was named FGF-2-pBS. Correct ligation was veri-
fied by sequence analysis using Alf-Express (Pharmacia, antibodies were also added without FGF-2 to study their
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intrinsic effects on proliferation. Medium was changed to determined microscopically using an Axiophot S100 mi-
croscope (Zeiss) by a blinded investigator, and the per-Iscove’s containing BrdU/FdU in a dilution of 1:500 four
hours prior to measurements. Cells were then washed centage of a-smooth muscle actin-positive cells was cal-
culated. Each experiment was repeated three timesthree times in PBS and fixed in methanol containing 2%
hydrogen peroxide followed by denaturation in 1N HCl independently.
for 10 minutes. After a further three times of washing
Matrix synthesisin PBS containing 0.1% Tween and blocking for 30 min-
utes in PBS (0.1% Tween, 3% BSA), 50 mL of anti-BrdU Enzyme-linked immunosorbent assay (ELISA) of su-
pernatants were performed as described [33], with someantibody were added and incubated for 45 minutes. Cells
were again washed three times in PBS/Tween, and perox- modifications, including the use of chemiluminescence
to enhance sensitivity [34]. Eight 3 103 cells were platedidase substrate was added (100 mL/well). Optical densi-
ties were subsequently determined photometrically at per well, and cells were again made quiescent by incuba-
tion in serum-free medium for 24 hours. Next, FGF-2405 nm (Dynatech MR 4000; Dynatech, Denkendorf,
Germany). All experiments were performed in triplicate was added in concentrations of 0.1, 1.0, and 10 ng/mL
followed by incubation for 48 hours. Human recombi-and repeated five times. Results are shown in percentage
of negative control (Iscove’s medium 5 100%). nant TGF-b1 (R&D Systems) in a concentration of 1
ng/mL served as a positive control. Fifty mg/mL ascorbicIn a third set of experiments, confluent monolayers of
fibroblasts were trypsinized, and cells were seeded at 4 3 acid and 50 mg/mL propionitrile (both from Sigma) were
added in experiments evaluating collagen synthesis. Su-103 cells per well in 96-well culture plates. After 12 hours,
DMEM medium was replaced by Iscove’s medium. After pernatants were transferred to a Maxisorpe plate and
incubated overnight at room temperature. Plates werea further 24 hours, cells were incubated with various
factors (FGF-2 at concentrations of 0.1, 1, 10, and 100 subsequently dried for two hours and blocked with 3%
dried milk. Incubation with 50 mL of the primary anti-ng/mL, FGF-2 (1 ng/mL) 1 FGF-neutralizing antibody
(10 mg/mL), FGF-2 (10 ng/mL) 1 irrelevant IgG, and body (anticollagen type I was used in a concentration
of 1:300 and antifibronectin at 1:5000) was followed byFGF-2 (1 ng/mL) 1 heparin (10 mg/mL) for 72 hours
before cell counts were performed. PDGF-BB at 10 washing two times with PBS/0.1% Tween and incubation
with the secondary antibody [antimouse-IgG-AP andng/mL and heparin alone (10 mg/mL) served as controls.
Again, all experiments were performed in triplicate and antirabbit-IgG-AP (both Boehringer Mannheim, Ger-
many), both used at a concentration of 1:1000]. Afterrepeated five times.
two additional wash steps, 100 mL of CSPD-Ready-to-
Immunofluorescence staining of a-smooth Use substrate (Boehringer Mannheim) were added, and
muscle actin quantitation was performed in a luminometer (Mikrolu-
mat CB 96P; Berthold, Bad Wildbad, Germany) usingThe effects of FGF-2 on the differentiation of kidney
fibroblasts into myofibroblasts were assessed by immu- MikroWine software (Mikrotek, Overath, Germany).
Nonspecific binding was determined by incubation withnofluorescent staining of a-smooth muscle actin after
continuous exposure to FGF-2 for 48 hours. Cells were the secondary antibody only. The value was normally
less than 5% of the total chemiluminescence and wasseeded in microchamber slides and incubated in regular
medium for 12 hours. After 24 hours of incubation in subtracted from each assay. All assays were performed
in triplicate and repeated five times. Standardization wasIscove’s medium for quiescence, FGF-2 was added in
concentrations of 0.1, 1.0, and 10 ng/mL. At the end of obtained for the collagen type I ELISA using human
type I collagen (Becton Dickinson, Bedford, MA, USA).incubation, cells were washed twice with PBS and fixed
with ethanol/acetic acid (50:50, vol/vol) for 20 minutes The limit of detection was 1 ng/mL, with a working range
of 10 to 1000 ng/mL. Human fibronectin (Sigma) servedat 48C. The cells were subsequently washed again and
incubated for two hours at room temperature with a as standard for the fibronectin ELISA. The working
range of that ELISA was 0.1 to 10 mg/mL, with a limit1:200 dilution of a monoclonal mouse antibody to human
a-actin isoform of smooth muscle cells. Cells were then of detection of 10 ng/mL. All values were corrected for
cell counts (103 cells), which were performed after trans-washed again with PBS and incubated for 60 minutes
at room temperature with the FITC-conjugated rabbit- fer of supernatants.
antimouse antibody. Control cultures were incubated
Evaluation of cell proliferation in vivowithout application of the primary antibody. Incubation
with TGF-b1 (1 ng/mL) served as a positive control. Immunostaining with MIB-1 (Dako) was used to eval-
uate cell proliferation in vivo. Five-micrometer thick sec-Cells with the typical a-actin structure were considered
to be a-actin positive. Additional staining with the tions were cut, dewaxed, and rehydrated according to
routine procedures. Sections were pretreated in a micro-Hoechst dye H33258 to identify nuclei was performed
to facilitate cell counting. For each group, 500 cells were wave oven for 5 minutes and then incubated for 60 min-
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utes at room temperature with the MIB-1 antibody, which
was used in a concentration of 1:50. The streptavidin-
biotin/alkaline phosphatase complex technique (Dako)
was performed, and Fast Rede was used as the chromo-
gen. The sections were counterstained with hematoxylin.
All stained nuclei were rated as positive. Proliferative
activity within the interstitium and tubular epithelium
was quantitated separately by counting MIB-1–positive
cells in four fields at 3250 magnification using an integra-
tion grid.
Statistical analysis
All values are expressed as mean 6 SEM unless spe-
cified. Analysis of variance (ANOVA) was used to de-
termine statistical differences between growth factor-
treated groups and controls using Sigma-State software
(Jandel Scientific, San Rafael, CA, USA). Further analy-
sis was carried out using Bonferroni’s test to control
for multiple testing. For nonnormally distributed data
(MIB-1 staining), the Mann–Whitney rank sum test was
applied. A correlation between semiquantitative intersti-
tial FGF-2 staining, morphometric volume, and MIB-1
positivity was evaluated by Spearman’s rank-order corre-
lation coefficient. P values , 0.05 were considered sig-
nificant.
RESULTS
Specificity of the anti-basic fibroblast growth
factor antibody
Since the exact localization of FGF-2 in the kidney is
still controversial, we first determined the specificity of
the antibody used for our studies. First, immunofluores-
Fig. 1. Specificity of the anti–basic fibroblast growth factor (anti-cence labeling demonstrated that the two fibroblast lines,
FGF-2) antibody. The two kidney fibroblast cell lines Tk 173 and TkTk 173 and Tk 188, were positive for FGF-2 using the
188 express FGF-2 as determined by Northern blot (A) and immunoblot
Ab-2 antibody. These results were corroborated by analyses (B). Northern blot gave a main band at 7.0 kb, as expected
for FGF-2 (A). Immunoblot analysis demonstrated a main band at 18Northern and Western blot analyses (Fig. 1). Northern
kD corresponding to the size of the recombinant protein. Additionalblot analysis confirmed that both fibroblast lines express
bands at 22.5 and 24 kD correspond to multiple transplantation initiation
FGF-2 mRNA, with a main band at 7.0 kb (Fig. 1A). In sites (B). One hundred micrograms of total cellular protein were loaded
onto each lane, and 50 ng of recombinant FGF-2 control proteinaddition, the immunoblot demonstrated that the anti-
(rFGF-2) served as positive control.body detects a specific 18 kd band in the two fibroblast
lines corresponding to the size of the recombinant pro-
tein (Fig. 1B). The two additional bands found mainly
in Tk 173 fibroblasts probably correspond to multiple nica media of blood vessels, few tubular (mainly distal
by morphology), and many, albeit not all, interstitial cellstranslation initiation sites [35]. There was no cross-reac-
tivity of the antibody with FGF-1 (acidic fibroblast (Fig. 2). The number of positive interstitial cells was
considerably smaller in paraffin sections, probably be-growth factor; data not shown).
cause of differences in antigen stability (data not shown).
Basic fibroblast growth factor expression is expressed To further characterize the FGF-2–positive cells within
in interstitial fibroblast-like cells and increased in the interstitium, immunofluorescent double labelings
kidneys with tubulointerstitial fibrosis were performed in normal kidneys and biopsies from
kidneys with minimal interstitial involvement (intersti-Basic fibroblast growth factor expression was first ana-
lyzed in frozen sections of normal kidneys by indirect tium morphometrically ,25%). The results are depicted
in Figure 2. Most of the FGF-2–positive cells within theimmunofluorescence. Immunolabeling of normal kid-
neys demonstrated FGF-2 protein within glomeruli, tu- interstitium stained also positive for CD 54 (intercellular
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Fig. 2. Localization of FGF-2–positive cells
in cortical tissue of a normal kidney by immu-
nofluorescence. Indirect immunofluorescence
double labelings for FGF-2 (FITC labeled)
and HLA-DR (A), CD 68 (B), a-smooth muscle
actin (C), cytokeratin (D), CD 54 (E), and
CD 44 (F ) (rhodamine labeled) were per-
formed in a human kidney without interstitial
scarring. There is a close correlation in stain-
ing within the interstitium for FGF-2 and
a-smooth muscle actin, CD 54, and CD 44.
However, some interstitial cells stain exclu-
sively for a-smooth muscle actin (C), some
exclusively for FGF-2 and not for CD 54 (E),
or CD 44 (F). A number of cells coexpress
FGF-2 and HLA-DR (A), although most in-
terstitial cells stain only for FGF-2. There are
very few coexpressions between FGF-2 and
CD 68 (B). Interstitial cells do not express
cytokeratin; however, some tubular cells dis-
play coexpression of FGF-2 and cytokeratin
(D). Original magnification 3200.
Fig. 3. Staining for FGF-2 in a fibrotic kidney. Indirect immunofluorescence for FGF-2 (A, C, E) and vimentin (B), a-smooth muscle actin (D),
and CD 44 (F ) in a human kidney with marked interstitial fibrosis. The staining for all four molecules is increased compared with a normal kidney.
There is marked coexpression for FGF-2 and all three markers of interstitial fibroblasts; however, again, the overlap in staining is not complete.
Some interstitial cells label exclusively for FGF-2 and some exclusively for a-smooth muscle actin (C and D). Original magnification 3400 (A and
B) and 3200 (C, D, E and F).
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adhesion molecule-1; Fig. 2E) and CD 44 (Fig. 2F), al- out significant interstitial scarring (numbers 14, 15, 33,
though many FGF-2–positive cells did not label for both. and 34). No increase in FGF-2 expression was observed
In addition, almost all FGF-2–positive cells did stain for in any of the four specimens. Thus, when FGF-2 protein
vimentin as well (data not shown). There was a consid- expression was correlated with the interstitial volume
erable overlap in interstitial staining for FGF-2 and only in those kidneys in which widening of the interstitial
a-smooth muscle actin (Fig. 2C); however, there were space was due to scarring, we found an even better corre-
some cells that expressed a-smooth muscle actin but lation (r 5 0.84, P , 0.01). Figure 4 illustrates the correla-
not FGF-2. There was some coexpression of FGF-2 and tion graphically.
HLA-DR (Fig. 2A), but most FGF-2–positive interstitial When the specimens from patients with glomerulone-
cells were negative for the HLA class II molecule, which phritis (N 5 20) were analyzed exclusively, the correla-
is expressed on dendritic cells and macrophages. Only tion was still significant (r 5 0.65, r , 0.01). The number
occasionally was coexpression of FGF-2 and the macro- of individual diseases was too small to analyze them
phage marker CD 68 observed (Fig. 2B), indicating that separately. However, looking at the specimens with IgA
only very few FGF-2–positive cells are macrophages. nephritis, there may be a biphasic expression pattern of
Judging by the difference in staining for CD 68 and FGF-2 with a 111 expression at interstitial volumes of
HLA-DR, some of the cells that stained for FGF-2 may 37 to 46% and a 11 expression at volumes of 55 to
be dendritic cells, but the majority clearly are not. CD 44, 71%. There was no correlation between interstitial
CD 54, and a-smooth muscle actin have all been propa- FGF-2 staining and interstitial volume in the specimens
gated as potential markers of fibroblasts [36, 37]. Thus, from patients with tubulointerstitial nephritis.
it seems reasonable to assume that most FGF-2–positive
cells within the interstitium are probably fibroblasts or FGF-2 protein expression is increased in cortical tissue
fibroblast-like cells. from kidneys with interstitial fibrosis
We next compared the sections from eight normal Although our immunofluorescence labeling studies
renal tissues (from 3 female and 5 male patients, mean had shown a good correlation between interstitial vol-
age 56.9 years) and 39 kidneys (from 12 female and 27 ume and interstitial FGF-2 labeling, we wanted to con-
male patients, mean age 45.0 years), each with varying firm this finding by immunoblot analysis. Thus, protein
degrees of tubulointerstitial fibrosis. Since we were par- was isolated from cortical tissue from three normal kid-
ticularly interested in the correlation between FGF-2 neys and six kidneys with marked interstitial scarring
expression and the degree of interstitial scarring, a vari- [from patients 10 (that is, FK1), 11 (FK2), 13 (FK3), 18
ety of renal diseases was examined. Table 1 displays the (FK4), 19 (FK5), and 24 (FK6)]. With the exception of
characteristics of patients and tissue types. The relative FK1, all fibrotic kidneys contained more FGF-2 thanpercentage of the cortical interstitium was determined by
their normal counterparts (Fig. 5A). Figure 5B summa-morphometric analysis. In normal kidneys, the relative
rizes the result after densitometric analysis (P 5 0.048).percentage of the interstitium varied between 15 and
25%. Conversely, in the nephrectomy specimens from In situ hybridizations reveal increased FGF-2 mRNA
patients with renal disease, the interstitium occupied be- expression within the tubulointerstitium in
tween 49 and 72%. No change of FGF-2 expression was end-stage kidneys
observed in normal human kidneys. However, robust
In situ hybridizations were performed to localize FGF-up-regulation of FGF-2 expression was noted in kidneys
2–synthesizing cells in three normal and three end-stagewith interstitial scarring. Table 1 summarizes the results.
kidneys with interstitial fibrosis, tubular atrophy, andFigure 3 depicts the staining results in a kidney with
dilation. As expected, hybridization with the sense probemarked interstitial fibrosis. FGF-2–positive cells (Fig. 3
gave no signal (Fig. 6A). Conversely, hybridization withA, C, and E) also stained positive for vimentin (Fig. 3B),
the antisense probe demonstrated weak staining withina-smooth muscle actin (Fig. 3D), and CD 44 (Fig. 3F).
glomeruli and blood vessels, as well as occasional tubularAgain, there was only little co-staining for the dendritic
and interstitial cells in normal kidneys (Fig. 6B), indi-cell and macrophage marker HLA-DR and only occa-
cating that these cells synthesize FGF-2 themselves.sional co-staining for the macrophage marker CD 68
Furthermore, similar to what was observed by immuno-(data not shown), excluding prominent expression in
fluorescent staining, in situ hybridizations of fibrotic end-these cells. In paraffin-embedded sections, there was an
stage kidneys revealed a robust increase in signal foraccentuation of extracellular matrix staining, including
FGF-2 mRNA within interstitial cells (Fig. 6 C, D). Thetubular basement membrane, whereas fewer cellular ele-
majority of interstitial cells displayed FGF-2 mRNA po-ments were labeled.
sitivity. There was also increased staining in tubular cells,When the expression of FGF-2 was correlated with
even in some tubules that were dilated and atrophic.the cortical interstitial volume, we found a good correla-
Conversely, there was no increased FGF-2 mRNA syn-tion (r 5 0.64, P , 0.01). However, four of the biopsy
thesis within the glomeruli of the analyzed kidneys, indi-specimens displayed an enlargement of the interstitial
volume caused exclusively by interstitial infiltration with- cating that most FGF-2 is, in fact, synthesized in nonglo-
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Table 1. Characteristics of the kidney specimens
Interstitial
Patient # Sex Age Tissue Diagnosis FGF-2 staining volume
1 M 68 Biopsy MGN 11 22%
2 M 31 Biopsy MGN 1 25%
3 F 47 Biopsy Chronic rejection 111 55%
4 M 69 Biopsy IgA nephropathy 111 46%
5 M 54 Biopsy Amyloidosis 11 48%
6 M 22 Biopsy RPGN 11 38%
7 M 27 Biopsy CRF 111 65%
8 M 34 Biopsy Chronic rejection 11 68%
9 M 60 Biopsy IgA nephropathy 11 55%
10 F 41 Nephrectomy ESRD 111 68%
11 M 83 Nephrectomy ESRD 11 61%
12 M 34 Biopsy IgA nephropathy 1 36%
13 M 59 Nephrectomy ESRD 111 76%
14 M 53 Biopsy TIN 1 78%
15 F 17 Biopsy TIN 1 50%
16 M 49 Biopsy Amyloidosis 11 40%
17 M 22 Biopsy RPGN 1 22%
18 F 71 Nephrectomy ESRD 111 72%
19 M 27 Nephrectomy ESRD 111 70%
20 F 28 Biopsy IgA nephropathy 11 37%
21 M 25 Biopsy IgA nephropathy 111 37%
22 M 25 Biopsy Chronic rejection 111 50%
23 M 48 Biopsy Diabetic nephropathy 11 31%
24 F 57 Nephrectomy ESRD 111 49%
25 F 43 Biopsy CRF 11 41%
26 M 27 Biopsy IgA nephropathy 11 42%
27 M 30 Biopsy FSGS 11 36%
28 M 42 Biopsy FSGS 1 18%
29 F 22 Nephrectomy Diabetic nephropathy 1 20%
30 F 58 Biopsy RPGN 11 46%
31 M 49 Biopsy FSGS 111 74%
32 M 17 Biopsy FSGS 1 27%
33 F 67 Biopsy TIN 1 70%
34 M 78 Biopsy TIN 1 46%
35 M 64 Biopsy MGN 1 18%
36 F 29 Biopsy MGN 11 42%
37 M 50 Biopsy FSGS 1 22%
38 F 67 Biopsy RPGN 11 25%
39 M 60 Biopsy IgA nephropathy 11 71%
40 F 64 Nephrectomy Normal kidney 1 23%
41 M 54 Nephrectomy Normal kidney 1 19%
42 M 45 Nephrectomy Normal kidney 1 25%
43 M 71 Nephrectomy Normal kidney 1 21%
44 F 53 Nephrectomy Normal kidney 1 15%
45 F 48 Nephrectomy Normal kidney 1 16%
46 M 61 Nephrectomy Normal kidney 1 24%
47 M 59 Nephrectomy Normal kidney 1 20%
There were 6 cases of end-stage renal disease (ESRD), 4 cases of acute tubulointerstitial nephritis (TIN), 4 cases of rapidly progressive glomerulonephritis (RPGN),
7 cases of IgA nephropathy, 4 cases of membranous glomerulonephritis (MGN), 5 cases of focal segmental glomerulosclerosis (FSGS), 3 cases of chronic transplant
rejection, 2 cases of amyloidosis, 2 cases of diabetic nephropathy, and 2 cases of chronic renal failure of unknown origin (CRF). Eight normal kidneys served as
controls. Interstitial FGF-2 labeling was determined semiquantitatively, and interstitial volume determined morphometrically. Interstitial FGF-2 staining was rated
as in normal kidneys (1), increased (11), or robustly increased (111).
merular cells. Thus, we conclude that the results of the low-affinity receptors were examined in seven primary
cortical fibroblast lines. All cell lines were characterizedin situ hybridizations parallel the protein stainings, dem-
as fibroblasts and synthesized extracellular matrix com-onstrating that increased FGF-2 mRNA synthesis takes
ponents, including collagen types I and III, as well asplace in interstitial cells within the kidney and that in-
fibronectin. Expression of FGFR-1, one of four high-creased protein detection is not due to mere accumula-
affinity receptors, was analyzed by immunoblot analysis.tion of extrarenally synthesized FGF-2.
The immunoblot analysis demonstrated a double band
Detection of FGF-2 expression and its low- and high- at approximately 120 kD in all seven fibroblast lines
affinity receptors in human primary cortical fibroblasts (Fig. 7A). The most robust expression of FGFR-1 was
observed in fibroblasts isolated from kidneys 25, 31, andTo evaluate the possible role of FGF-2 in human renal
fibrogenesis, the expression of FGF-2 and its high- and 39, with interstitial volumes of 41, 74, and 79%, respec-
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Fig. 4. Correlation of staining for FGF-2 and morphometric volume.
There was a positive correlation between semiquantitative FGF-2 label-
ing and morphometrically determined volume. Four cases of acute
tubulointerstitial nephritis have been omitted for this analysis (discussed
in the Results section). P , 0.01; r 5 0.84, by Spearman’s rank order
coefficient.
tively. In addition, FACS analyses confirmed the expres-
sion of heparan sulfate proteoglycane, which serves as
a low-affinity receptor for FGF-2 in all seven cell lines.
There was no difference in the level of expression (data
not shown).
Fig. 5. Expression of FGF-2 protein in kidneys with and without inter-Basic fibroblast growth factor protein itself could also
stitial scarring. FGF-2 protein expression was examined by immunoblotbe detected in all seven fibroblast lines studied (Fig. analysis in three normal (NK1 through NK3) and six kidneys with at
7B). Interestingly, the level of FGF-2 protein expression least 10% interstitial fibrosis (FK1 through FK6). With the exception
of FK1, all fibrotic kidneys express more FGF-2 than their nonfibroticcorrelated with the degree of interstitial scarring of the
counterparts (A). (B) The densitometric analysis. *P , 0.05.kidney from which the cells were isolated. Whereas F33
and F34, isolated from patients 33 and 34 with tubuloin-
terstitial nephritis and no interstitial scarring, displayed
relatively moderate positivity for FGF-2, the level of (187.8 6 8.9%) at a concentration of 1 ng/mL. The maxi-
expression was much higher in the fibroblasts isolated mum increase was seen with a concentration of 10 ng/mL
from kidneys with interstitial scarring. In addition, there after 72 hours (267.3 6 24.9%). Figure 8 summarizes the
was a good correlation between the relative level of findings obtained with bromodeoxyuridine incorpora-
FGF-2 protein expression in the seven fibroblast lines tion after stimulation with FGF-2 at a concentration of
and the semiquantitative FGF-2 immunofluorescence la- 1 ng/mL for 72 hours in three of the five fibroblast lines.
beling in the kidneys from which the cells were isolated F25 and F26 were isolated from biopsies of patients 25
(r 5 0.76, P 5 0.038). and 26, displaying increased interstitial volumes because
of fibrosis of 41 and 42%, respectively. Conversely, F34
FGF-2 is a strong mitogen for renal fibroblasts, originated from patient 34 with tubulointerstitial nephri-
induces differentiation into myofibroblasts, and has no tis and no interstitial scarring. Bromodeoxyuridine incor-
major effect on matrix protein synthesis poration was increased between 166.3 6 3.2% in F34
To evaluate the function of FGF-2, proliferation, dif- cells and 247.0 6 15.4% in F26 fibroblasts. This increase
ferentiation into myofibroblasts, and matrix protein syn- could be specifically inhibited by addition of a neutraliz-
thesis of human renal fibroblasts were examined in five ing antibody to FGF-2, whereas a nonrelevant IgG did
different primary cortical fibroblast lines. In a first set not have an effect on FGF-2–induced proliferation. In-
of experiments, performed in F25 fibroblasts, FGF-2 terestingly, the addition of the FGF-2 neutralizing anti-
caused a robust induction of proliferation, which was body alone did decrease bromodeoxyuridine incorpora-
time and dose dependent. The increase of bromodeoxy- tion in all five fibroblast lines. However, because of the
low level of basal proliferative activity, that decrease wasuridine incorporation was significant after 48 hours
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Fig. 6. In situ hybridizations for FGF-2 in normal control kidney and end-stage kidneys. There is no staining in a normal kidney hybridized with
the FGF-2 sense riboprobe (A). Hybridization of a normal kidney with the FGF-2 antisense riboprobe revealed faint staining of some glomerular,
tubular, vascular, and interstitial (arrows) cells. The hybridization signal was robustly up-regulated in kidneys from patients with end-stage renal
disease (C and D). Staining for FGF-2 mRNA was concentrated within the interstitium (C) and in some tubular cells (D), even in some tubules
that appear atrophic (C). Conversely, there was no increased staining for FGF-2 mRNA within glomeruli. Original magnification 3200 (A, B, and
D) and 3100 (C).
statistically significant in only three cell lines (maximum cle actin, which serves as a marker for myofibroblast
formation. In two primary cortical fibroblast lines, F6inhibition 31.5% in F25 cells). Conversely, the addition
of the nonrelevant IgG resulted in either no change or isolated from a kidney with mild interstitial scarring (in-
terstitial volume 38%) and F39 from a kidney with anan increase in bromodeoxyuridine uptake. In a third set
of proliferation experiments, bromodeoxyuridine incor- interstitial volume of 71%, FGF-2 resulted in a time-
and dose-dependent induction of a-smooth muscle actinporation essays were confirmed by cell counting. In these
experiments, cell numbers increased dose dependently expression. Figure 9 summarizes the results observed
after 72 hours. The increase was similar to that obtainedto a maximal 234.3 6 15.8% (P , 0.01) in F25 and to
197.4 6 18.6% (P , 0.01) in F34 fibroblasts after 96 hours with TGF-b1 (increase of a-smooth muscle actin-positive
cells from 52.3 6 3.3 to 82.3 6 1.9% after 72 hours ofof incubation at a concentration of 10 ng/mL. Again,
the higher concentration (100 ng/mL) did not have any incubation with 1 ng/mL FGF-2; P , 0.01). Of course,
we do not know if these changes were due to de novosuperior effect to the 10 ng/mL concentration. There was
no additional effect of heparin, which by itself caused a expression of a-smooth muscle actin or due to clonal
selection of positive cells caused by cell population heter-slight reduction in proliferation (maximum inhibition of
18.9 6 4.5%; NS). ogeneity.
Finally, the influence of FGF-2 on extracellular matrixActivation of fibroblasts into so-called myofibroblasts
represents a key step in renal fibrogenesis. We evaluated synthesis was evaluated by ELISAs for collagen type I
and fibronectin in F6 and F39 fibroblasts. Whereasthe effects of FGF-2 on the expression of a-smooth mus-
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Fig. 7. Expression of FGF-2 and FGFR-1 in seven primary cortical
fibroblast lines. (A) The expression of FGFR-1. (B) The expression of
FGF-2 by immunoblot analyses. F33 and F34 were isolated from kidney
biopsies without interstitial scarring, and the other five fibroblast lines
were from kidneys with moderate (F25 and F26) and severe interstitial
scarring (F24, F31, and F39). There was a good correlation between
the degree of interstitial scarring and the expression of FGF-2, however,
no such correlation could be found regarding the expression of FGFR-1
(discussed in the Results section).
TGF-b1 (at a concentration of 1 ng/mL) increased secre-
tion of collagen type I (from 101.0 6 9.8 ng/103 cells to
Fig. 8. Effects of FGF-2 on proliferation in primary cortical fibroblasts.1018.9 6 98.5 ng/103 cells in F39 fibroblasts after stimula- FGF-2 was added in a concentration 1.0 ng/mL to F26 (A), F25 (B),
tion for 48 h) and fibronectin (from 31.8 6 4.5 mg/103 cells and F34 (C) fibroblasts and proliferation was determined after 72 hours
by bromodeoxyuridine incorporation. Specificity was determined byto 48.7 6 3.5 mg/103 cells, again after 48 h of stimulation)
the addition of a neutralizing FGF-2 antibody and a nonspecific immu-compared with controls in both cell lines, no significant noglobulin (IgG). FGF-2 induced a robust proliferative response in
effect could be observed using three different concentra- all three fibroblast lines, which could be blocked specifically by the
neutralizing FGF-2 antibody. The addition of the neutralizing FGF-2tions of FGF-2, although there was a tendency for a
antibody alone resulted in a significant inhibition of proliferation indecrease in secretion for collagen type I in both cell lines two of the three tested cell lines, whereas the nonspecific IgG resulted
(data not shown). rather in a promitogenic response. Values are given in percentage of
negative control (Iscove’s medium) and are a mean of five independent
experiments. All experiments were conducted in triplicates. *P , 0.05Increased FGF-2 expression correlates with increased
vs. control; **P , 0.01 vs. control.interstitial and tubular MIB-1 staining
After having established that FGF-2 is a mitogen for
human cortical kidney fibroblasts in vitro, we tried to
determine whether increased FGF-2 expression was cor- Fifteen patient specimens could not be analyzed because
of the lack of tissue that had been used up for otherrelated with increased proliferative activity in vivo. Thus,
we stained for expression of the Ki-67 antigen, which is purposes (specimens from patients 5, 7, 14 through 17,
21, 23, 27, 29, 30, 32, and 35 through 37). In normalassociated with cell proliferation using the MIB-1 anti-
body. We were able to perform stainings for MIB-1 in kidneys, only few interstitial and tubular cells displayed
MIB-1 positivity (median 1.5 in both; Fig. 10A), whereascortical tissue from 24 patients and 8 normal controls.
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Fig. 9. Expression of a-smooth muscle actin
in primary cortical fibroblasts. The number
of a-smooth muscle actin-positive cells was
determined after incubation with three differ-
ent concentrations of FGF-2 (0.1, 1.0, or 10
ng/mL) for 48 hours. Iscove’s medium served
as a negative control, and TGF-b1 (1 ng/mL)
served as a positive control. FGF-2 induced
the expression of a-smooth muscle actin in
both cell lines significantly. **P , 0.01 vs.
control.
the number of MIB-1–positive cells was considerably 11). There does not seem to be a correlation of FGF-2
staining with acute inflammatory processes, although thehigher in patient specimens (median 13.5, P 5 0.001 in
number of tissues studied is too limited in that regard.interstitial, median 9.0, P 5 0.008 in tubular cells; Fig.
10 B–D). The highest number of MIB-1–positive cells
within the interstitium was observed in the two biopsies DISCUSSION
from patients with tubulointerstitial nephritis (numbers
Virtually all forms of chronic progressive renal disease33 and 34), which is not surprising given the high prolifer-
are accompanied by changes in the tubulointerstitium,ative activity of infiltrating monocytes/macrophages and
irrespective of the primary renal disease [38]. This is notlymphocytes. When the number of MIB-1–positive cells
surprising since renal tubules, interstitium, and vascula-was correlated with the semiquantitative FGF-2 staining,
ture comprise more than 80% of the renal cortex [39].there was a positive correlation with the number of inter-
Tubulointerstitial changes consist of interstitial inflam-stitial (r 5 0.48, P , 0.01) and tubular (r 5 0.53, P ,
mation followed by fibrosis, tubular atrophy, and dila-
0.01) positive cells. However, the correlation was much
tion. Along with glomerular scarring, interstitial fibrosis
more robust when we omitted the two patients with acute is an accurate predictor of renal function, even for pri-
interstitial nephritis, who had a high proliferative activity mary glomerular diseases [29]. One of the most per-
of infiltrating mononuclear cells but a low level intersti- plexing features of renal fibrogenesis is the fact that
tial FGF-2 staining. In that case (N 5 30), correlation fibrosis often progresses despite resolution of the pri-
of FGF-2 staining with MIB-1–positive interstitial cells mary inflammatory stimulus [40]. Thus, we and others
(r 5 0.71, P , 0.01) and tubular cells (r 5 0.66, P , have propagated the existence of autocrine cytokine
0.01) was much better. The results are displayed in Figure loops, which may represent one of the key differences
11. Thus, the results of the MIB-1 staining demonstrate between regular wound healing and scarring [41–43].
that FGF-2 positivity is correlated positively with the The current studies that combined descriptional and
number of MIB-1–positive cells within the interstitium functional analyses were undertaken to elucidate the
and in tubular epithelia in scarring processes. This was role of FGF-2 in renal fibrogenesis. We have carefully
even true when glomerular diseases were analyzed sepa- analyzed the usefulness of the antibody used in our study
rately with a positive correlation between FGF-2 staining given the controversial information regarding the detec-
and interstitial MIB-1 positivity (r 5 0.64, P , 0.05), tion of FGF-2. Different splice variants may be the rea-
son that a variety of studies came to different conclusionsalthough the number of analyzed tissues was small (N 5
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Fig. 10. Immunohistochemical staining for MIB-1–positive cells. Whereas normal kidneys displayed either no or only occasional MIB-1–positive
cells (A), staining of kidneys with variable degrees of interstitial scarring demonstrate positive tubular and interstitial cells (highlighted by arrows).
(B) Taken from patient 4 (IgA nephritis, interstitial space 46%, FGF-2 111). (C) Taken from patient 36 (SLE, interstitial space 42%, FGF-2 11).
(D) Taken from patient 10 (end-stage renal disease caused by amyloidosis, interstitial space 68%, FGF-2 111). Original magnification 3400.
regarding the localization of FGF-2. As was shown in sections also synthesize FGF-2 mRNA. In addition, we
have demonstrated for the first time that the expressionthe medullary Tk 173 and Tk 188 fibroblasts, the Ab-2
antibody mainly detects the 18 kD band, but also the of FGF-2 protein and mRNA is increased in kidneys
with tubulointerstitial scarring, irrespective of the pri-22.5 and 24 kD bands described previously [35]. These
higher molecular weight forms may target intracellular mary disease. Furthermore, our study has shown that
primary cortical fibroblasts express FGF-2 and one ofFGF-2 to a nuclear localization [44]; however, their exact
role is currently unclear. The higher molecular weight its high-affinity receptors. FGF-2 causes a robust induc-
tion in proliferation in these cells and induces a-smoothforms could not be detected in our primary cortical fibro-
blasts. Thus, the 18 kD band seems to be the dominating muscle actin expression as marker for myofibroblast for-
mation but has no major effect on synthesis of collagenisoform in kidney fibroblasts.
Our study demonstrates that FGF-2 protein can be type I and fibronectin. Proliferative activity in tubular
epithelial and interstitial cells is increased in diseaseddetected in glomerular, vascular, a few (mainly distal)
tubular, as well as interstitial fibroblast-like cells in nor- human kidneys and correlates with staining for FGF-2.
Finally, basal proliferation in cortical fibroblasts can bemal human kidneys. In cryosections, more interstitial
cells were labeled than in paraffin-embedded tissue sec- reduced by the addition of a neutralizing antibody to
FGF-2, pointing to a possible autocrine mechanism oftions, which may explain the differences to the study by
Floege et al, who described only occasional interstitial fibroblast proliferation. Thus, our study provides evi-
dence for the existence of an autocrine loop in humancell positivity [18]. The in situ hybridizations confirmed
that the same cells that stain positive for FGF-2 in cyro- renal fibrogenesis, which is characterized by constitutive
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knockout mice display delayed wound healing [47], fur-
ther pointing to a critical role for the cytokine in matrix
formation. Unlike most other polypeptide growth fac-
tors, FGF-2 lacks a conventional leader sequence for
secretion, and the mechanisms for its release are still
unclear [11]. Chronically injured cells, however, release
FGF-2 efficiently, and the mitogenic effect of the cyto-
kine is potentiated by tissue injury [48]. In addition, as
was originally shown by Mignatti, Morimoto, and Rifkin,
FGF-2 may be secreted by viable cells [49].
What is the role of proliferation in renal fibrogenesis?
Proliferation was thought to play only a little role, if at
all, in the progression of renal disease. However, as was
demonstrated by Nadasdy et al in a study of 28 human
end-stage kidneys, even scarred kidneys display high pro-
liferative activity in tubuli and interstitial cells [50]. Simi-
lar results were recently described by Thomas et al in
the subtotal nephrectomy model of chronic renal failure
[51]. These findings are corroborated by our study. It
is intriguing to speculate that fibroblasts and tubular
epithelial cells stimulate each other in the process of
renal fibrogenesis, as indicated by the paralleled prolifer-
ation. We and others have recently demonstrated that
tubular epithelial cells may acquire certain characteris-
tics of fibroblasts [27, 52]. Although we did not examine
this aspect in the current study, FGF-2 may be a candi-
date cytokine that could play a role in that process.
Clearly, the interaction between tubular epithelial cells
and fibroblasts plays a role not only in the initiation of
interstitial inflammation, but also in progressive renal
scarring. In the study by Ray et al in their transgenic
mouse model of HIV-associated nephropathy, FGF-2
detection was associated with interstitial areas that con-
Fig. 11. Correlation of interstitial FGF-2 labeling with MIB-1–positive tained both cell injury and proliferation [25]. Thus, pro-
interstitial (A) and tubular epithelial (B) cells. There was a positive
liferation does play a critical role in the progression ofcorrelation between semiquantitative FGF-2 labeling and the number
of proliferating interstitial (A; P , 0.01, r 5 0.71), as well as tubular renal disease, and autocrine/paracrine secretion of FGF-2
epithelial (B; P , 0.01, r 5 0.66) cells. Two cases of acute tubulointersti- may be important in the perpetuation of the process.
tial nephritis have been omitted for this analysis (see results for details).
Autocrine stimulation of cell proliferation caused byThe r depicts the value for Spearman’s rank order coefficient.
FGF-2 has been described in a number of cells, including
tubular epithelial [43], endothelial [53], and vascular
smooth muscle [54] cells. In these cell types, as in cortical
expression of FGF-2 and its receptors, up-regulation in fibroblasts, the efficacy of the neutralizing antibody indi-
disease state, induction of proliferation, and decreased cates that the protein does get secreted before binding
proliferation after neutralization of the cytokine. to its receptors.
The increased expression of FGF-2 in renal fibrogen- Basic fibroblast growth factor exerts its effects via low-
esis, although demonstrated for the first time, is not sur- and four high-affinity receptors. The high-affinity recep-
prising. The association of FGF-2 expression with prolif- tors consist of four transmembrane tyrosine kinases
erative fibrogenesis was first demonstrated by Gonzalez (FGFR-1 to -4) [11]. Our study has demonstrated that
et al in patients with Dupuytren’s contracture [45]. They primary cortical fibroblasts express FGFR-1, also known
noted already intense staining for FGF-2 associated with as flg, and heparan sulfate proteoglycan, which potenti-
increased synthesis for FGF-2 and FGFR-1 mRNA in ates the binding to the high-affinity receptors [55]. Floege
fibroblasts. Charlotte et al found increased expression et al noted occasional interstitial staining for flg [18]. In
of FGF-2 in the carbon tetrachloride model of rat liver our study, only three of the five examined fibroblast lines
fibrosis [46]. In that study, FGF-2 expression was local- from kidneys with interstitial fibrosis displayed an up-
regulated expression for FGFR-1. One possible explana-ized to myofibroblastic liver cells. Interestingly, FGF-2
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tion is the redundancy of the fibroblast receptor system, relating with the degree of interstitial injury. Morita et
including multiple splice variants. In a recent study by al examined the expression of FGF-2 binding domains
Ford et al, all seven receptor isoforms assayed by the in human kidneys. FGF-2 binding heparan sulfate do-
group were expressed in whole cortex by reverse tran- mains are present in the basement membrane proteogly-
scription-polymerase chain reaction assay [56]. Thus, in- can perlecan, but are absent from other glycosaminogly-
creased expression of one of the other high-affinity re- cans such as fibroglycan and glypican [64]. Heparan
ceptors may explain the lack of up-regulation of FGFR-1 sulfate was detected in sections with glomerular sclerosis
in two kidneys with interstitial scarring. Alternatively, and interstitial fibrosis; however, only the fibrotic sec-
down-regulation of FGFR-1 during a late stage of fibro- tions contained FGF-2 binding [65]. Interestingly, a small
genesis may protect the kidney from uncontrolled prolif- population of macrophage-like parenchymal cells was
eration. The mechanism of overexpression of FGF-2 and identified in that study which expressed the FGF-2–
FGFR-1 has been described in certain tumor cells, in- binding domain on the cell surface, which is in concor-
cluding human hepatoma cells [57]. dance with the results of our study.
Heparan sulfate proteoglycan is a low-affinity receptor No significant effect of FGF-2 on synthesis of matrix
for FGF-2. Its expression in all seven primary cortical components was observed in our study, although there
fibroblasts may explain why heparin (which otherwise is was a tendency for decreased synthesis of collagen type I.
known to increase the proliferative effects of FGF-2) Decreased synthesis of collagen type I in cells of mesen-
did not have any additional effects on proliferation. Con- chymal origin after incubation with FGF-2 has been de-
versely, the slight reduction in proliferation caused by scribed before. Tan et al, for example, demonstrated a
heparin itself may be explained by competition with this down-regulation of collagen gene expression in keloid
low-affinity receptor [58]. fibroblasts [66]. Thus, unlike TGF-b1, a role of FGF-2
Our findings of FGF-2 and FGFR-1 detection in hu- in the accumulation of extracellular matrix is not sup-
man kidney fibroblasts or fibroblast-like cells are in con- ported by our study nor by the literature. However,
cordance with observations by other groups in dermal FGF-2 does induce expression of a-smooth muscle actin
[59], mammary gland [60], and human liver [61] fibro- as an indicator of myofibroblast formation. In that re-
blasts. However, we extend those findings, demonstra- gard, it is similar to TGF-b1, which is the prototype of
ting that renal fibroblasts (or fibroblast-like cells) do a profibrogenic cytokine in the kidney. Expression of
express FGF-2 in vivo as well. The interstitial cells that a-smooth muscle actin has been correlated with intersti-
express FGF-2 are predominantly renal fibroblast-like tial matrix formation and even with prognosis in a num-
cells as shown by double labelings. Vimentin, a-smooth ber of studies in the kidney [67] and other organs [68].
muscle actin, CD 44, and CD 54 are all markers for It certainly represents a critical step in fibrogenesis [69].
fibroblasts in the kidney [36, 37]. However, though al- In summary, we have demonstrated that FGF-2 is ex-
most all CD 44- and CD 54-positive cells within the pressed in interstitial fibroblast-like cells and that it is
interstitium expressed FGF-2, some interstitial cells dis- robustly up-regulated within these and tubular epithelial
played exclusive FGF-2 positivity. In addition, a number cells in human kidney fibrosis. Whereas FGF-2 does not
of a-smooth muscle actin-positive cells were negative for seem to play a role in interstitial matrix production, it
FGF-2. Renal interstitial fibroblasts are a heterogeneous may have a critical role in fibroblast proliferation and
population [62], and studies on these cells are still ham- myofibroblast formation. The continuity of fibroblast
pered by the lack of a definite fibroblast marker [1]. Most proliferation is probably one of the major differences
of these cells seem to express FGF-2 in vivo, although between fibrosis and restitutional healing. Our study
some subpopulations may not. Conversely, some nonfi- points to an important role of FGF-2 in that process.
broblast cells such as monocytes/macrophages or den- Clearly, further studies are necessary that delineate the
dritic cells express FGF-2, although the majority of these
differences between regular wound healing with no or
cells do not under normal conditions.
minor scar formation and interstitial fibrosis resulting inPrevious studies suggested that extrarenal sources may
progressive loss of organ function.contribute to FGF-2 deposition in the kidney [25]. Al-
though we cannot completely exclude that possibility, it
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